Inventiva is burning cash at approximately 3,000% of revenue — an extreme rate — and its market capitalization of roughly $890 million falls below the $1 billion minimum threshold that defines the investable universe for this strategy, removing it from consideration. RSI at 18 and a falling-knife technical setup compound the risk, though the long-term moving average slope remains positive, suggesting the selloff may not yet have found a durable floor.
Thesis pillars
- Extreme Cash Burn Vs Revenue→Stable
- Below Minimum Market Cap Floor↓Deteriorating
- Capitulation Level Rsi Ambiguous Trend↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Inventiva S.A. - American Depos (IVA) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $3.32: Quality below floor (3.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: Elevated put/call ratio: 10.00; Below-average business quality; Negative price momentum.
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a... Read more
Sell if holding. Engine safety override at $3.32: Quality below floor (3.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: Elevated put/call ratio: 10.00; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.7/10, moderate confidence.
Passes 6/9 gates (clean insider activity, no SEC red flags, news boost analyst 0.50, earnings proximity 175d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: speculative.
Recent developments
updated 2026-10-09Recent Developments — Inventiva S.A. - American Depos
Latest news
- NEWS Guggenheim Sticks to Its Buy Rating for Inventiva (IVA) - The Globe and Mail — The Globe and Mail positive
- NEWS Analysts Offer Insights on Healthcare Companies: Surgery Partners (SGRY), Envista Holdings (NVST) and Inventiva (IVA) - — The Globe and Mail positive
- NEWS WTA roundup: Defending champ Iva Jovic returns to Guadalajara final - Reuters — Reuters neutral
- NEWS Inventiva S.A. (IVA): Analyst Ratings Signal A 297% Upside Potential For Biotech Innovator - DirectorsTalk Interviews — DirectorsTalk Interviews positive
- NEWS Truist Securities Maintains Buy on Inventiva, Raises Price Target to $18 — benzinga Oct 2, 2026 positive
Generated 2026-10-09T05:51:57Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $3.32: Quality below floor (3.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: Elevated put/call ratio: 10.00; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $3.09. Score 4.7/10, moderate confidence.
Take-profit target: $4.17 (+25.6% upside). Prior stop was $3.09. Stop-loss: $3.09.
DATA_ISSUE: analyst_target_implausible (raw $15.20 vs price $3.32 — ratio 4.6×). Rejected, falling back to technical TP.; Quality below floor (3.7 < 4.0).
Inventiva S.A. - American Depos trades at a P/E of N/A (forward -4.5). TrendMatrix value score: 5.0/10. Verdict: Sell.
17 analysts cover IVA with a consensus score of 4.4/5. Average price target: $15.
What does Inventiva S.A. - American Depos do?Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies...
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.